Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free Uloric-related heart injury cases. Here at Leading Justice, we can customize your firm’s Uloric advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Uloric cardiovascular injury and death advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to Uloric and side effects like cardiovascular injury and heart-related death, Leading Justice will increase your firm’s Uloric caseload. If you are interested in helping victims of Uloric side effects, our direct advertising strategies and extensive consumer reach at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we categorize claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will custom tailor our Uloric heart injury intake specifications to the exact criteria you are seeking. So, if your firm has specific Uloric qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Uloric heart attack and death data with no chance of fraud.
Uloric Cardiovascular Injury and Death Litigation
Uloric (febuxostat) is a prescription gout medication that was once considered the first line of treatment for hyperuricemia, or excessive uric acid levels in the blood. When Uloric was approved by the U.S. Food and Drug Administration (FDA) in 2009, it became the first prescription drug in 40 years to be approved to lower uric acid levels in gout patients. The FDA had previously rejected Takeda Pharmaceuticals’ application to approve Uloric twice before, due to concerns about the potential risk of cardiovascular side effects associated with the gout medication. And when the FDA finally did approve the drug, it did so on the condition that Takeda conduct a post-marketing study to assess cardiac outcomes in patients taking Uloric compared to those taking another gout medication called allopurinol. The results of the study, known as the CARES trial, were published in March 2018, and showed that gout patients taking Uloric faced a statistically significant increased risk of death.
Prior to receiving the final results of the CARES trial, the FDA had issued a drug safety communication warning Uloric users that preliminary results from the clinical trial showed an increased risk of heart-related death with Uloric treatment. In February 2019, almost exactly 10 years after the FDA approved Uloric for the chronic management of hyperuricemia in gout patients, the agency updated that initial communication, warning that Uloric use was tied to an increased risk of heart-related death and death from all causes. At that time, the FDA required that a Boxed Warning be added to the Uloric label alerting users to the risk of heart-related death from Uloric and also restricted the approved use of Uloric, once a first-line therapy for adults with gout, to patients who are not treated effectively or who experience severe side effects with allopurinol. With its use restricted, fewer patients are being prescribed Uloric as a treatment for gout, but because Takeda aggressively marketed the drug for years without disclosing its cardiovascular side effects, Uloric was prescribed to millions of people who were unaware of the serious health risks it could pose.